MCID: HRD004
MIFTS: 56

Hereditary Breast Ovarian Cancer

Categories: Genetic diseases, Reproductive diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Hereditary Breast Ovarian Cancer

MalaCards integrated aliases for Hereditary Breast Ovarian Cancer:

Name: Hereditary Breast Ovarian Cancer 12 14
Hereditary Breast and Ovarian Cancer Syndrome 56 29 42 69
Breast/ovarian Cancer, Hereditary 24

Characteristics:

Orphanet epidemiological data:

56
hereditary breast and ovarian cancer syndrome
Inheritance: Autosomal dominant; Age of onset: All ages;

Classifications:



External Ids:

Disease Ontology 12 DOID:5683
MeSH 42 D061325
NCIt 47 C8493
Orphanet 56 ORPHA145
UMLS via Orphanet 70 C0677776
ICD10 via Orphanet 34 C50 C56
UMLS 69 C0677776

Summaries for Hereditary Breast Ovarian Cancer

Disease Ontology : 12 An autosomal dominant disease characterized by the higher than normal tendency to develop breast and ovarian cancers in genetically related families.

MalaCards based summary : Hereditary Breast Ovarian Cancer, also known as hereditary breast and ovarian cancer syndrome, is related to colorectal cancer and brca1 hereditary breast and ovarian cancer syndrome. An important gene associated with Hereditary Breast Ovarian Cancer is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are Gene Expression and Cell Cycle, Mitotic. The drugs Letrozole and Estrogen Antagonists have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and ovary, and related phenotypes are Decreased homologous recombination repair frequency and cellular

Wikipedia : 72 Hereditary breast–ovarian cancer syndromes (HBOC) are cancer syndromes that produce higher than normal... more...

Related Diseases for Hereditary Breast Ovarian Cancer

Diseases in the Hereditary Breast Ovarian Cancer family:

Breast-Ovarian Cancer, Familial, 2 Breast-Ovarian Cancer, Familial 4
Breast-Ovarian Cancer, Familial, 1 Breast-Ovarian Cancer, Familial 3
Rad51c-Related Familial Susceptibility to Breast-Ovarian Cancer Rad51d-Related Familial Susceptibility to Breast-Ovarian Cancer

Diseases related to Hereditary Breast Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
id Related Disease Score Top Affiliating Genes
1 colorectal cancer 25.6 BRCA1 BRCA2 CHEK2 MLH1 MSH2 PMS1
2 brca1 hereditary breast and ovarian cancer syndrome 12.1
3 brca2 hereditary breast and ovarian cancer syndrome 12.1
4 primitive neuroectodermal tumor of the corpus uteri 10.9 BRCA1 BRCA2
5 bronchopulmonary dysplasia 10.9 BRCA1 BRCA2
6 cutaneous lupus erythematosus 10.9 BRCA1 BRCA2
7 autoimmune disease of blood 10.8 BRCA1 BRCA2
8 selective immunoglobulin deficiency disease 10.8 BRCA1 BRCA2
9 baraitser-winter cerebrofrontofacial syndrome 10.8 BRCA1 BRCA2 PALB2
10 bacteremia 10.7 BRCA1 BRCA2 PALB2
11 endocervicitis 10.7 BRCA1 BRCA2 TP53
12 breast pericanalicular fibroadenoma 10.7 BRCA1 BRCA2 TP53
13 extracranial neuroblastoma 10.7 BRCA1 BRCA2 TP53
14 retinal detachment 10.7 BRCA1 BRCA2 TP53
15 distal monosomy 7q36 10.7 BRCA1 BRCA2 TP53
16 mycetoma 10.7 BRCA1 BRCA2 TP53
17 ductal carcinoma in situ 10.7 BRCA1 BRCA2 TP53
18 fallopian tube carcinosarcoma 10.7 BRCA1 BRCA2 TP53
19 pancreatic cancer 4 10.7 BRCA1 BRCA2 NBN
20 dental caries 10.7 BRCA1 BRCA2 TP53
21 nasal cavity disease 10.7 BRCA1 BRCA2 TP53
22 trachea carcinoma in situ 10.6 BRCA1 BRCA2 TP53
23 mixed cerebral palsy 10.6 BRCA2 PALB2 TP53
24 estrogen-receptor negative breast cancer 10.6 BRCA1 BRCA2 TP53
25 thai symphalangism syndrome 10.6 BRCA2 TP53
26 glanders 10.6 BRCA2 BRIP1 RAD51
27 spastic paraplegia 72, autosomal recessive 10.5 MRE11 RAD50
28 breast myoepithelial neoplasm 10.4 PTEN TP53
29 chest wall lymphoma 10.4 BRCA1 BRCA2 PTEN TP53
30 pulmonary fibrosis, idiopathic susceptibility 10.3 BRCA2 CHEK2 PTEN
31 amyloid tumor 10.2 BRCA1 BRCA2 CHEK2 PALB2 RAD51
32 endometriosis of uterus 10.2 MLH1 PTEN TP53
33 pediatric cns choriocarcinoma 10.1 PMS1 STK11
34 acute cholinergic dysautonomia 10.0 MSH2 TP53
35 prostate cancer, hereditary, x-linked 1 10.0 PTEN STK11 TP53
36 viral encephalitis 10.0 BRCA1 BRCA2 PTEN STK11
37 dubin-johnson syndrome 9.9 PTEN STK11 TP53
38 large intestine adenocarcinoma 9.9 MLH1 MSH2
39 optic nerve sheath meningioma 9.9 MLH1 MSH2
40 bleeding disorder, platelet-type, 13 9.9 BRCA2 PTEN STK11 TP53
41 fallopian tube mucinous adenocarcinoma 9.9 PMS1 STK11
42 nail disorder, nonsyndromic congenital, 1 9.9 BRCA1 BRCA2 MLH1 PTEN TP53
43 rectum squamous cell carcinoma 9.9 MLH1 TP53
44 benign fibrous mesothelioma 9.8 MLH1 MSH2
45 lichen nitidus 9.8 MSH2 TP53
46 psoriasis 9.8 MLH1 MSH2
47 familial episodic pain syndrome 9.8 MLH1 MSH2 TP53
48 endometrial cancer 9.8
49 pancreatic cancer 9.8
50 heart disease 9.8

Graphical network of the top 20 diseases related to Hereditary Breast Ovarian Cancer:



Diseases related to Hereditary Breast Ovarian Cancer

Symptoms & Phenotypes for Hereditary Breast Ovarian Cancer

GenomeRNAi Phenotypes related to Hereditary Breast Ovarian Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10.72 BARD1 BRCA1 RAD51
2 Decreased homologous recombination repair frequency GR00151-A-2 10.72 BRCA1 RAD51
3 Decreased homologous recombination repair frequency GR00236-A-1 10.72 BARD1 BRCA1 BRCA2 PALB2 RAD51
4 Decreased homologous recombination repair frequency GR00236-A-2 10.72 BARD1 BRCA1 BRCA2 PALB2 RAD51 IGFBP4
5 Decreased homologous recombination repair frequency GR00236-A-3 10.72 BARD1 BRCA1 BRCA2 PALB2 RAD51
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.39 CHEK2 MLH1 MRE11 NBN PALB2 PTEN
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.39 BRIP1 CHEK2 MLH1 MRE11 NBN PALB2
8 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 10.16 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
9 Increased cell death HMECs cells GR00103-A-0 9.8 IGFBP4 PTEN RAD51 RAD51C TP53 BRCA1
10 Decreased viability with cisplatin GR00101-A-4 9.77 RAD51 BARD1 BRCA1 BRCA2 BRIP1
11 Synthetic lethal with cisplatin GR00101-A-1 9.55 BARD1 BRCA1 BRCA2 BRIP1 RAD51
12 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.1 BARD1 BRCA1 BRCA2 MRE11 MSH2 RAD51D

MGI Mouse Phenotypes related to Hereditary Breast Ovarian Cancer:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.41 MSH2 NBN PALB2 PTEN RAD50 RAD51
2 embryo MP:0005380 10.29 BARD1 BRCA1 BRCA2 MRE11 NBN PALB2
3 growth/size/body region MP:0005378 10.25 RAD51D STK11 TP53 BARD1 BRCA1 BRCA2
4 endocrine/exocrine gland MP:0005379 10.23 BRCA1 BRCA2 BRIP1 CHEK2 IGFBP4 MLH1
5 homeostasis/metabolism MP:0005376 10.22 PTEN RAD51D STK11 TP53 BRCA1 BRCA2
6 mortality/aging MP:0010768 10.16 NBN PALB2 PTEN RAD50 RAD51 BARD1
7 digestive/alimentary MP:0005381 10.1 BRCA1 BRCA2 MLH1 MSH2 PTEN RAD50
8 neoplasm MP:0002006 10.03 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
9 integument MP:0010771 10.02 BRCA1 BRCA2 MLH1 MSH2 PALB2 PTEN
10 limbs/digits/tail MP:0005371 9.87 BRCA1 BRCA2 PALB2 PTEN RAD50 RAD51D
11 nervous system MP:0003631 9.8 NBN PALB2 PTEN RAD50 RAD51D STK11
12 reproductive system MP:0005389 9.36 BRCA1 BRCA2 BRIP1 MLH1 MRE11 NBN

Drugs & Therapeutics for Hereditary Breast Ovarian Cancer

Drugs for Hereditary Breast Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
2 Estrogen Antagonists Phase 3,Phase 2
3 Estrogens Phase 3,Phase 2
4 Hormone Antagonists Phase 3,Phase 2
5 Hormones Phase 3,Phase 2
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
7 Aromatase Inhibitors Phase 3
8 Steroid Synthesis Inhibitors Phase 3
9
Tamoxifen Approved Phase 2 10540-29-1 2733526
10
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
11
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
12
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
13
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
14
Zoledronic acid Approved Phase 2 118072-93-8 68740
15
Olaparib Approved Phase 2 763113-22-0 23725625
16
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
17
Doxil Approved June 1999 Phase 2 31703
18 Antineoplastic Agents, Hormonal Phase 2
19 Bone Density Conservation Agents Phase 2
20 Estrogen Receptor Modulators Phase 2
21 Selective Estrogen Receptor Modulators Phase 2
22 Antimitotic Agents Phase 2,Phase 1
23 Albumin-Bound Paclitaxel Phase 2,Phase 1
24 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
25 Poly(ADP-ribose) Polymerase Inhibitors Phase 2,Phase 1
26 Alkylating Agents Phase 2
27 Anti-Bacterial Agents Phase 2
28 Antibiotics, Antitubercular Phase 2
29 Antirheumatic Agents Phase 2
30 Immunosuppressive Agents Phase 2
31 Topoisomerase Inhibitors Phase 2
32 Diphosphonates Phase 2
33 Citrate Nutraceutical Phase 2
34
Citric Acid Nutraceutical, Vet_approved Phase 2 77-92-9 311
35
Veliparib Investigational Phase 1 912444-00-9 11960529
36
Ethanol Approved 64-17-5 702
37
Menthol Approved 2216-51-5 16666

Interventional clinical trials:

(show top 50) (show all 53)

id Name Status NCT ID Phase Drugs
1 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
2 Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children Completed NCT00685256 Phase 3
3 Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers Recruiting NCT03162276 Phase 3
4 Methods in Education for Breast Cancer Genetics Active, not recruiting NCT00001806 Phase 3
5 Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation Active, not recruiting NCT00673335 Phase 3 letrozole;Placebo
6 Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer Completed NCT01333748 Phase 2
7 Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer Completed NCT00253539 Phase 2 arzoxifene hydrochloride;tamoxifen citrate
8 Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers Completed NCT01367639 Phase 2
9 Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer Completed NCT00321633 Phase 2 carboplatin;docetaxel
10 The Women Choosing Surgical Prevention (WISP) Trial Recruiting NCT02760849 Phase 2
11 Neoadjuvant Carboplatin in Triple Negative Breast Cancer Recruiting NCT02978495 Phase 2 Doxorubicin;Carboplatin;Paclitaxel;Cyclophosphamide
12 A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer Recruiting NCT02203513 Phase 2 LY2606368
13 Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Active, not recruiting NCT00305695 Phase 2 Zoledronic Acid
14 Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer Active, not recruiting NCT00679783 Phase 2 AZD2281
15 Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer Completed NCT00535119 Phase 1 Carboplatin;Paclitaxel;Veliparib
16 Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy Active, not recruiting NCT00892736 Phase 1 Veliparib
17 Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer Unknown status NCT00855998
18 Korean Hereditary Breast Cancer Study Unknown status NCT00595348
19 Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer Unknown status NCT01139957
20 Hypodontia and Ovarian Cancer Unknown status NCT01470235
21 Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment Unknown status NCT01273909
22 Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC) Completed NCT00829959
23 Statewide Communication to Reach Diverse Low Income Women Completed NCT02956681
24 Cancer Genetics Hereditary Cancer Panel Testing Completed NCT02324062
25 Telemedicine vs. Face-to-Face Cancer Genetic Counseling Completed NCT00609505
26 Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk Completed NCT00735150
27 Risk Education and Assessment for Cancer Heredity Completed NCT01346761
28 Lessons Learned From the Family Gene Toolkit Completed NCT02154633
29 Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer Recruiting NCT03075540
30 Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling Recruiting NCT03225170
31 Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland Recruiting NCT03124212
32 Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry Recruiting NCT02302742
33 Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes. Recruiting NCT03246841
34 Risk-Reducing Surgeries for Hereditary Ovarian Cancer Recruiting NCT03294343
35 Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk Recruiting NCT02705924
36 Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers Recruiting NCT02516540
37 Specimen and Data Study for Ovarian Cancer Early Detection and Prevention Recruiting NCT00005095
38 Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer Recruiting NCT02560818
39 Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients Recruiting NCT01789684
40 Familial Cancer Registry and DNA Bank Recruiting NCT02083224
41 Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation Recruiting NCT02664389
42 Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer Active, not recruiting NCT02786147
43 Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer Active, not recruiting NCT01230346
44 Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers Active, not recruiting NCT02087592
45 Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer Active, not recruiting NCT00040222
46 Radical Fimbriectomy for Young BRCA Mutation Carriers Active, not recruiting NCT01608074
47 Increase Surveillance for Breast and Ovarian Cancers, Also to Determine Targeted Risk-reducing and Preventative Strategies Active, not recruiting NCT03319290
48 OVArian Cancer Non-Interventional Study - OVATAR Active, not recruiting NCT02122588
49 Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility Enrolling by invitation NCT02133703
50 Inherited Susceptible Genes Among Epithelial Ovarian Cancer Not yet recruiting NCT03015376

Search NIH Clinical Center for Hereditary Breast Ovarian Cancer

Cochrane evidence based reviews: hereditary breast and ovarian cancer syndrome

Genetic Tests for Hereditary Breast Ovarian Cancer

Genetic tests related to Hereditary Breast Ovarian Cancer:

id Genetic test Affiliating Genes
1 Hereditary Breast and Ovarian Cancer Syndrome 29
2 Breast/ovarian Cancer, Hereditary 24

Anatomical Context for Hereditary Breast Ovarian Cancer

MalaCards organs/tissues related to Hereditary Breast Ovarian Cancer:

39
Breast, Testes, Ovary, Bone, Prostate, Heart

Publications for Hereditary Breast Ovarian Cancer

Articles related to Hereditary Breast Ovarian Cancer:

(show top 50) (show all 77)
id Title Authors Year
1
Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol. ( 28931501 )
2017
2
High frequency of the recurrent c.1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast-ovarian cancer prevention and control. ( 28577564 )
2017
3
Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast/ovarian cancer. ( 26969308 )
2016
4
Modeling the dyadic effects of parenting, stress, and coping on parent-child communication in families tested for hereditary breast-ovarian cancer risk. ( 26848859 )
2016
5
Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas. ( 27532258 )
2016
6
Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome. ( 26943589 )
2016
7
MA1llerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery. ( 26875157 )
2016
8
Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: report from the creighton university hereditary cancer registry with review of the implications. ( 25756400 )
2015
9
Should risk-reducing surgery in women from hereditary breast ovarian cancer families be confined to removal of the fallopian tubes with ovarian conservation? ( 26246179 )
2015
10
BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk. ( 26047126 )
2015
11
RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families. ( 26406419 )
2015
12
The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry. ( 24916970 )
2014
13
Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases. ( 23935836 )
2013
14
Genetic counseling does not fulfill the counselees' need for certainty in hereditary breast/ovarian cancer families: an explorative assessment. ( 22777929 )
2013
15
The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters. ( 22740372 )
2013
16
Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists. ( 24021253 )
2013
17
BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries. ( 23697973 )
2012
18
Adverse childhood experiences of persons at risk for Huntington's disease or BRCA1/2 hereditary breast/ovarian cancer. ( 21895638 )
2012
19
Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. ( 21203900 )
2011
20
Unpacking the blockers: understanding perceptions and social constraints of health communication in hereditary breast ovarian cancer (HBOC) susceptibility families. ( 21547418 )
2011
21
Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. ( 20169665 )
2010
22
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. ( 23199084 )
2010
23
Hereditary breast ovarian cancer syndromes in the Maritimes. ( 20181317 )
2010
24
Hereditary breast-ovarian cancer syndrome in Russia. ( 22649661 )
2010
25
Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. ( 18821011 )
2009
26
A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. ( 19178933 )
2009
27
Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. ( 19292801 )
2009
28
Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. ( 19008092 )
2009
29
The prevalence of hereditary breast/ovarian cancer risk in patients with a history of breast or ovarian cancer in Japanese subjects. ( 20149041 )
2009
30
Brief assessment of parents' attitudes toward testing minor children for hereditary breast/ovarian cancer genes: development and validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS). ( 18385162 )
2009
31
Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer. ( 19820364 )
2009
32
BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. ( 19241424 )
2009
33
Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer. ( 19016756 )
2008
34
Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases. ( 19066131 )
2008
35
Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. ( 18410690 )
2008
36
Psychological and cancer-specific distress at 18 months post-testing in women with demonstrated BRCA1 mutations for hereditary breast/ovarian cancer. ( 18219587 )
2008
37
BRCA1 and BRCA2 risk perceptions among African American women at increased risk for hereditary breast-ovarian cancer. ( 18417966 )
2008
38
A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer. ( 17131039 )
2007
39
Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. ( 17898808 )
2007
40
Hereditary breast-ovarian cancer: clinical findings and medical management. ( 17901820 )
2007
41
Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer. ( 16980814 )
2006
42
Acceptance of genetic testing for hereditary breast ovarian cancer among study enrollees from an African American kindred. ( 16523520 )
2006
43
Germline mutations of BRCA1 in two Korean hereditary breast/ovarian cancer families. ( 16465413 )
2006
44
Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. ( 16527602 )
2006
45
Decision making and decision support for hereditary breast-ovarian cancer susceptibility. ( 16045423 )
2005
46
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. ( 15863145 )
2005
47
Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations". ( 16188301 )
2005
48
Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families. ( 15846789 )
2005
49
Clinical, molecular and geographical features of hereditary breast/ovarian cancer in latvia. ( 20223033 )
2005
50
Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. ( 16252621 )
2005

Variations for Hereditary Breast Ovarian Cancer

ClinVar genetic disease variations for Hereditary Breast Ovarian Cancer:

6 (show top 50) (show all 1479)
id Gene Variation Type Significance SNP ID Assembly Location
1 BRCA2 NM_000059.3(BRCA2): c.6275_6276delTT (p.Leu2092Profs) deletion Pathogenic rs11571658 GRCh37 Chromosome 13, 32914767: 32914768
2 BRCA2 NM_000059.3(BRCA2): c.6591_6592delTG (p.Glu2198Asnfs) deletion Pathogenic rs80359605 GRCh37 Chromosome 13, 32915083: 32915084
3 BRCA2 NM_000059.3(BRCA2): c.5722_5723delCT (p.Leu1908Argfs) deletion Pathogenic rs80359530 GRCh37 Chromosome 13, 32914214: 32914215
4 BRCA2 NM_000059.3(BRCA2): c.2808_2811del (p.Ala938Profs) deletion Pathogenic rs80359351 GRCh37 Chromosome 13, 32911300: 32911303
5 BRCA2 NM_000059.3(BRCA2): c.5946delT (p.Ser1982Argfs) deletion Pathogenic rs80359550 GRCh37 Chromosome 13, 32914438: 32914438
6 BRCA2 NM_000059.3(BRCA2): c.771_775delTCAAA (p.Asn257Lysfs) deletion Pathogenic rs80359671 GRCh37 Chromosome 13, 32905145: 32905149
7 BRCA2 NM_000059.3(BRCA2): c.8537_8538delAG (p.Glu2846Glyfs) deletion Pathogenic rs80359714 GRCh37 Chromosome 13, 32945142: 32945143
8 BRCA2 NM_000059.3(BRCA2): c.658_659delGT (p.Val220Ilefs) deletion Pathogenic rs80359604 GRCh37 Chromosome 13, 32903606: 32903607
9 BRCA2 NM_000059.3(BRCA2): c.4648G> T (p.Glu1550Ter) single nucleotide variant Pathogenic rs80358695 GRCh37 Chromosome 13, 32913140: 32913140
10 BRCA2 NM_000059.3(BRCA2): c.5645C> G (p.Ser1882Ter) single nucleotide variant Pathogenic rs80358785 GRCh37 Chromosome 13, 32914137: 32914137
11 BRCA2 NM_000059.3(BRCA2): c.9196C> T (p.Gln3066Ter) single nucleotide variant Pathogenic rs80359180 GRCh37 Chromosome 13, 32954222: 32954222
12 BRCA2 NM_000059.3(BRCA2): c.631+1G> A single nucleotide variant Pathogenic rs81002897 GRCh37 Chromosome 13, 32900751: 32900751
13 BRCA2 NM_000059.3(BRCA2): c.631+2T> G single nucleotide variant Pathogenic rs81002899 GRCh37 Chromosome 13, 32900752: 32900752
14 BRCA1 NM_007294.3(BRCA1): c.181T> G (p.Cys61Gly) single nucleotide variant Pathogenic rs28897672 GRCh37 Chromosome 17, 41258504: 41258504
15 BRCA1 NM_007294.3(BRCA1): c.68_69delAG (p.Glu23Valfs) deletion Pathogenic rs80357783 GRCh37 Chromosome 17, 41276047: 41276048
16 BRCA1 NM_007294.3(BRCA1): c.1175_1214del40 (p.Leu392Glnfs) deletion Pathogenic rs80359874 GRCh37 Chromosome 17, 41246334: 41246373
17 BRCA1 NM_007294.3(BRCA1): c.2296_2297delAG (p.Ser766Terfs) deletion Pathogenic rs80357780 GRCh37 Chromosome 17, 41245251: 41245252
18 BRCA1 NM_007294.3(BRCA1): c.2681_2682delAA (p.Lys894Thrfs) deletion Pathogenic rs80357971 GRCh37 Chromosome 17, 41244866: 41244867
19 BRCA1 NM_007294.3(BRCA1): c.3005delA (p.Asn1002Thrfs) deletion Pathogenic rs80357601 GRCh38 Chromosome 17, 43092526: 43092526
20 BRCA1 NM_007294.3(BRCA1): c.3607C> T (p.Arg1203Ter) single nucleotide variant Pathogenic rs62625308 GRCh37 Chromosome 17, 41243941: 41243941
21 BRCA1 NM_007294.3(BRCA1): c.3748G> T (p.Glu1250Ter) single nucleotide variant Pathogenic rs28897686 GRCh37 Chromosome 17, 41243800: 41243800
22 BRCA1 NM_007294.3(BRCA1): c.3756_3759delGTCT (p.Ser1253Argfs) deletion Pathogenic rs80357868 GRCh37 Chromosome 17, 41243789: 41243792
23 BRCA1 NM_007294.3(BRCA1): c.4065_4068delTCAA (p.Asn1355Lysfs) deletion Pathogenic rs80357508 GRCh37 Chromosome 17, 41243480: 41243483
24 BRCA1 NM_007294.3(BRCA1): c.4327C> T (p.Arg1443Ter) single nucleotide variant Pathogenic rs41293455 GRCh37 Chromosome 17, 41234451: 41234451
25 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh37 Chromosome 17, 41209082: 41209082
26 BRCA1 NM_007294.3(BRCA1): c.2389G> T (p.Glu797Ter) single nucleotide variant Pathogenic rs62625306 GRCh37 Chromosome 17, 41245159: 41245159
27 BRCA1 NM_007294.3(BRCA1): c.843_846delCTCA (p.Ser282Tyrfs) deletion Pathogenic rs80357919 GRCh37 Chromosome 17, 41246702: 41246705
28 BRCA1 NM_007294.3(BRCA1): c.3481_3491delGAAGATACTAG (p.Glu1161Phefs) deletion Pathogenic rs80357877 GRCh37 Chromosome 17, 41244057: 41244067
29 BRCA1 NM_007294.3(BRCA1): c.1556delA (p.Lys519Argfs) deletion Pathogenic rs80357662 GRCh37 Chromosome 17, 41245992: 41245992
30 BRCA1 NM_007294.3(BRCA1): c.211A> G (p.Arg71Gly) single nucleotide variant Pathogenic/Likely pathogenic rs80357382 GRCh37 Chromosome 17, 41258474: 41258474
31 BRCA1 NM_007294.3(BRCA1): c.5324T> G (p.Met1775Arg) single nucleotide variant Pathogenic rs41293463 GRCh37 Chromosome 17, 41203088: 41203088
32 BRCA1 NM_007294.3(BRCA1): c.5324T> A (p.Met1775Lys) single nucleotide variant Pathogenic rs41293463 GRCh37 Chromosome 17, 41203088: 41203088
33 BRCA1 NM_007294.3(BRCA1): c.1674delA (p.Gly559Valfs) deletion Pathogenic rs80357600 GRCh37 Chromosome 17, 41245874: 41245874
34 BRCA1 NM_007294.3(BRCA1): c.1016delA (p.Lys339Argfs) deletion Pathogenic rs80357618 GRCh37 Chromosome 17, 41246532: 41246532
35 BRCA1 NM_007294.3(BRCA1): c.1018delG (p.Val340Terfs) deletion Pathogenic rs80357774 GRCh37 Chromosome 17, 41246530: 41246530
36 BRCA1 NM_007294.3(BRCA1): c.1121delC (p.Thr374Asnfs) deletion Pathogenic rs80357612 GRCh37 Chromosome 17, 41246427: 41246427
37 BRCA1 NM_007294.3(BRCA1): c.135-1G> T single nucleotide variant Pathogenic rs80358158 GRCh37 Chromosome 17, 41258551: 41258551
38 BRCA1 NM_007294.3(BRCA1): c.1360_1361delAG (p.Ser454Terfs) deletion Pathogenic rs80357969 GRCh37 Chromosome 17, 41246187: 41246188
39 BRCA1 NM_007294.3(BRCA1): c.1389_1390delAAinsG (p.Thr464Profs) indel Pathogenic rs273897659 GRCh37 Chromosome 17, 41246158: 41246159
40 BRCA1 NM_007294.3(BRCA1): c.143delT (p.Met48Serfs) deletion Pathogenic rs80357637 GRCh37 Chromosome 17, 41258542: 41258542
41 BRCA1 NM_007294.3(BRCA1): c.1444_1447delATTA (p.Ile482Terfs) deletion Pathogenic rs80357801 GRCh37 Chromosome 17, 41246101: 41246104
42 BRCA1 NM_007294.3(BRCA1): c.1480C> T (p.Gln494Ter) single nucleotide variant Pathogenic rs80357010 GRCh37 Chromosome 17, 41246068: 41246068
43 BRCA1 NM_007294.3(BRCA1): c.1504_1508delTTAAA (p.Leu502Alafs) deletion Pathogenic rs80357888 GRCh37 Chromosome 17, 41246040: 41246044
44 BRCA1 NM_007294.3(BRCA1): c.1510delC (p.Arg504Valfs) deletion Pathogenic rs80357908 GRCh37 Chromosome 17, 41246038: 41246038
45 BRCA1 NM_007294.3(BRCA1): c.1687C> T (p.Gln563Ter) single nucleotide variant Pathogenic rs80356898 GRCh37 Chromosome 17, 41245861: 41245861
46 BRCA1 NM_007294.3(BRCA1): c.1953_1956delGAAA (p.Lys653Serfs) deletion Pathogenic rs80357526 GRCh37 Chromosome 17, 41245592: 41245595
47 BRCA1 NM_007294.3(BRCA1): c.1960A> T (p.Lys654Ter) single nucleotide variant Pathogenic rs80357355 GRCh37 Chromosome 17, 41245588: 41245588
48 BRCA1 NM_007294.3(BRCA1): c.1961delA (p.Lys654Serfs) deletion Pathogenic rs80357522 GRCh37 Chromosome 17, 41245587: 41245587
49 BRCA1 NM_007294.3(BRCA1): c.2071delA (p.Arg691Aspfs) deletion Pathogenic rs80357688 GRCh37 Chromosome 17, 41245477: 41245477
50 BRCA1 NM_007294.3(BRCA1): c.2105dupT (p.Leu702Phefs) duplication Pathogenic rs80357880 GRCh37 Chromosome 17, 41245443: 41245443

Expression for Hereditary Breast Ovarian Cancer

Search GEO for disease gene expression data for Hereditary Breast Ovarian Cancer.

Pathways for Hereditary Breast Ovarian Cancer

Pathways related to Hereditary Breast Ovarian Cancer according to GeneCards Suite gene sharing:

(show all 36)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 BARD1 BRCA1 BRIP1 CHEK2 MLH1 MRE11
2
Show member pathways
13.5 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
3
Show member pathways
13.25 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
4
Show member pathways
13.09 BARD1 BRCA1 BRIP1 CHEK2 MLH1 MRE11
5
Show member pathways
13.03 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
6
Show member pathways
12.8 BARD1 BRCA1 BRCA2 CHEK2 MRE11 MSH2
7
Show member pathways
12.75 BARD1 BRCA1 BRIP1 CHEK2 MRE11 NBN
8 12.71 BRCA2 MLH1 MSH2 PTEN RAD51 TP53
9
Show member pathways
12.61 BRCA1 BRCA2 MLH1 MRE11 NBN RAD50
10 12.61 BRCA1 BRCA2 BRIP1 CHEK2 MLH1 MRE11
11
Show member pathways
12.5 BRCA1 BRCA2 MLH1 MSH2 PTEN TP53
12
Show member pathways
12.5 BARD1 BRCA1 CHEK2 MRE11 NBN RAD50
13
Show member pathways
12.5 BRCA1 CHEK2 MRE11 NBN PTEN RAD50
14
Show member pathways
12.36 BARD1 BRCA1 BRCA2 BRIP1 MRE11 NBN
15
Show member pathways
12.31 MRE11 NBN RAD50 TP53
16
Show member pathways
12.23 BRCA1 CHEK2 PTEN TP53
17 12.21 CHEK2 MLH1 MSH2 PTEN STK11 TP53
18 12.18 BARD1 BRCA1 BRCA2 CHEK2 MRE11 MSH2
19
Show member pathways
12.08 BARD1 BRCA1 BRCA2 BRIP1 MRE11 NBN
20 12.06 MLH1 MSH2 PTEN TP53
21 12.05 BRCA1 BRCA2 BRIP1 MLH1 PALB2 RAD51
22
Show member pathways
11.99 BRCA1 CHEK2 MRE11 NBN RAD50 RAD51
23
Show member pathways
11.83 MLH1 MSH2 PMS1
24 11.79 BRCA1 MLH1 MSH2 TP53
25 11.74 BRCA1 CHEK2 PTEN TP53
26 11.65 MRE11 NBN RAD50
27 11.64 CHEK2 MRE11 NBN RAD50 STK11
28 11.61 BARD1 BRCA1 CHEK2 NBN TP53
29
Show member pathways
11.57 BARD1 BRCA1 BRCA2 CHEK2 MRE11 MSH2
30
Show member pathways
11.47 CHEK2 MLH1 MSH2
31 11.44 BARD1 BRCA1 MRE11 NBN RAD50 RAD51
32
Show member pathways
11.42 MLH1 MSH2 TP53
33 11.29 BRCA1 MRE11 NBN RAD50
34
Show member pathways
11 MRE11 NBN RAD50
35 10.89 BARD1 BRCA1 CHEK2 MRE11 MSH2 PTEN
36 10.35 CHEK2 TP53

GO Terms for Hereditary Breast Ovarian Cancer

Cellular components related to Hereditary Breast Ovarian Cancer according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 chromosome GO:0005694 9.97 BRCA1 MLH1 MRE11 NBN RAD50 RAD51D
2 condensed nuclear chromosome GO:0000794 9.73 BRCA1 MLH1 RAD50 RAD51
3 site of double-strand break GO:0035861 9.71 MRE11 NBN RAD50 RAD51
4 condensed chromosome GO:0000793 9.7 BRCA1 MLH1 RAD51
5 lateral element GO:0000800 9.65 BRCA1 BRCA2 RAD51
6 chromosome, telomeric region GO:0000781 9.65 CHEK2 MRE11 NBN RAD50 RAD51D
7 Mre11 complex GO:0030870 9.63 MRE11 NBN RAD50
8 PML body GO:0016605 9.63 CHEK2 MRE11 NBN PTEN RAD51 TP53
9 replication fork GO:0005657 9.62 NBN RAD51C RAD51D TP53
10 MutLalpha complex GO:0032389 9.56 MLH1 PMS1
11 BRCA1-A complex GO:0070531 9.55 BARD1 BRCA1
12 nucleoplasm GO:0005654 9.55 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
13 Rad51B-Rad51C-Rad51D-XRCC2 complex GO:0033063 9.54 RAD51C RAD51D
14 BRCA1-BARD1 complex GO:0031436 9.51 BARD1 BRCA1
15 nuclear chromosome, telomeric region GO:0000784 9.5 BRCA2 MRE11 MSH2 NBN RAD50 RAD51
16 nucleus GO:0005634 10.32 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1

Biological processes related to Hereditary Breast Ovarian Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Name GO ID Score Top Affiliating Genes
1 double-strand break repair via nonhomologous end joining GO:0006303 9.97 BARD1 BRCA1 MLH1 MRE11 NBN RAD50
2 double-strand break repair GO:0006302 9.97 BRCA1 BRCA2 BRIP1 CHEK2 MRE11 MSH2
3 reciprocal meiotic recombination GO:0007131 9.93 MLH1 MRE11 RAD50 RAD51 RAD51C RAD51D
4 response to ionizing radiation GO:0010212 9.92 BRCA1 RAD51C RAD51D STK11
5 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.92 BRCA1 BRCA2 CHEK2 MLH1 MSH2
6 DNA duplex unwinding GO:0032508 9.91 BRIP1 MRE11 NBN RAD50
7 DNA synthesis involved in DNA repair GO:0000731 9.9 BARD1 BRCA1 BRCA2 BRIP1 MRE11 NBN
8 meiotic cell cycle GO:0051321 9.89 MRE11 NBN RAD50 RAD51
9 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.88 BRCA2 CHEK2 MSH2 TP53
10 DNA double-strand break processing GO:0000729 9.88 BARD1 BRCA1 MRE11 NBN RAD50
11 nucleotide-excision repair GO:0006289 9.86 BRCA2 RAD51D TP53
12 telomere maintenance GO:0000723 9.86 NBN RAD50 RAD51D
13 mismatch repair GO:0006298 9.85 MLH1 MSH2 PMS1
14 response to gamma radiation GO:0010332 9.85 BRCA2 CHEK2 TP53
15 DNA damage checkpoint GO:0000077 9.85 BRIP1 CHEK2 NBN
16 synapsis GO:0007129 9.85 BRIP1 MLH1 MRE11
17 response to X-ray GO:0010165 9.85 BRCA2 MSH2 RAD51 TP53
18 chromosome organization GO:0051276 9.84 BRCA2 MRE11 RAD51D
19 cellular response to gamma radiation GO:0071480 9.84 CHEK2 RAD51 TP53
20 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.84 BRCA1 BRCA2 CHEK2 TP53
21 positive regulation of protein autophosphorylation GO:0031954 9.82 MRE11 NBN RAD50
22 positive regulation of kinase activity GO:0033674 9.81 MRE11 NBN RAD50
23 isotype switching GO:0045190 9.81 MLH1 MSH2 NBN
24 telomere maintenance via recombination GO:0000722 9.81 BRCA2 RAD50 RAD51 RAD51C
25 mitotic recombination GO:0006312 9.8 RAD51 RAD51C RAD51D
26 positive regulation of telomere maintenance GO:0032206 9.78 MRE11 NBN RAD50
27 strand invasion GO:0042148 9.76 RAD51 RAD51C RAD51D
28 telomeric 3 overhang formation GO:0031860 9.74 MRE11 NBN RAD50
29 somatic hypermutation of immunoglobulin genes GO:0016446 9.73 MLH1 MSH2
30 mitotic G2 DNA damage checkpoint GO:0007095 9.72 MRE11 NBN
31 intra-S DNA damage checkpoint GO:0031573 9.72 MRE11 MSH2
32 DNA damage response, signal transduction by p53 class mediator GO:0030330 9.72 NBN TP53
33 postreplication repair GO:0006301 9.72 BRCA1 MSH2
34 determination of adult lifespan GO:0008340 9.71 MSH2 TP53
35 inner cell mass cell proliferation GO:0001833 9.71 BRCA2 PALB2
36 replicative senescence GO:0090399 9.71 CHEK2 TP53
37 positive regulation of isotype switching to IgG isotypes GO:0048304 9.71 MLH1 MSH2
38 protein K6-linked ubiquitination GO:0085020 9.7 BARD1 BRCA1
39 chromosome organization involved in meiotic cell cycle GO:0070192 9.7 RAD50 RAD51
40 negative regulation of telomere capping GO:1904354 9.7 NBN RAD50
41 somatic recombination of immunoglobulin gene segments GO:0016447 9.7 MLH1 MSH2
42 strand displacement GO:0000732 9.7 BARD1 BRCA1 BRCA2 BRIP1 MRE11 NBN
43 positive regulation of isotype switching to IgA isotypes GO:0048298 9.69 MLH1 MSH2
44 meiotic DNA recombinase assembly GO:0000707 9.69 RAD51C RAD51D
45 chordate embryonic development GO:0043009 9.68 BRCA1 BRCA2
46 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.66 MLH1 MSH2
47 regulation of mitotic recombination GO:0000019 9.65 MRE11 RAD50
48 mitotic recombination-dependent replication fork processing GO:1990426 9.65 BRCA2 RAD51
49 double-strand break repair via homologous recombination GO:0000724 9.28 BRCA1 BRCA2 MRE11 NBN PALB2 RAD50
50 cellular response to DNA damage stimulus GO:0006974 10.25 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1

Molecular functions related to Hereditary Breast Ovarian Cancer according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.97 BRIP1 CHEK2 RAD50 RAD51 RAD51C RAD51D
2 ATP binding GO:0005524 9.9 BRIP1 CHEK2 MLH1 MSH2 PMS1 RAD50
3 ATPase activity GO:0016887 9.86 MLH1 MSH2 PMS1 RAD50
4 protein C-terminus binding GO:0008022 9.85 BRCA2 MRE11 MSH2 RAD51
5 double-stranded DNA binding GO:0003690 9.8 MRE11 MSH2 RAD51 RAD51C RAD51D
6 damaged DNA binding GO:0003684 9.78 BRCA1 MSH2 NBN TP53
7 endodeoxyribonuclease activity GO:0004520 9.69 MRE11 RAD51 RAD51D
8 mismatched DNA binding GO:0030983 9.63 MLH1 MSH2 PMS1
9 recombinase activity GO:0000150 9.61 RAD51 RAD51C RAD51D
10 ATP-dependent DNA helicase activity GO:0004003 9.56 BRIP1 MRE11 NBN RAD50
11 single-stranded DNA endodeoxyribonuclease activity GO:0000014 9.54 MRE11 RAD50
12 DNA-dependent ATPase activity GO:0008094 9.54 RAD51 RAD51C RAD51D
13 guanine/thymine mispair binding GO:0032137 9.52 MLH1 MSH2
14 four-way junction DNA binding GO:0000400 9.26 MSH2 RAD51 RAD51C RAD51D
15 single-stranded DNA binding GO:0003697 9.17 BRCA2 MLH1 MSH2 PMS1 RAD51 RAD51C
16 protein binding GO:0005515 10.5 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
17 DNA binding GO:0003677 10.1 BRCA1 BRCA2 BRIP1 MRE11 MSH2 PALB2

Sources for Hereditary Breast Ovarian Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....